SU 11654
Latest Information Update: 04 Aug 2009
At a glance
- Originator Pfizer
- Class
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 13 Feb 2002 Preclinical trials in Cancer in USA (unspecified route)